This book provides health professionals and scientists with a comprehensive overview of the mesothelioma - an asbestos induced malignancy. It includes chapters on epidemology, diagnosis, histopathology, radiology, surgery, chemotherapy, immune therapy, and radiotherapy as well as the molecular biology and future therapies.

Whether you're a newly diagnosed Mesothelioma patient, a survivor,or a friend or relative of either, this book offers help. The only book to provide the doctor's and patient's views, 100 Questions & Answers About Mesothelioma gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, legal options, and much more. This outstanding team of authors -- led by a world-class lung disease expert -- provides an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease.

This book offers an updated review of malignant mesothelioma, including the latest advances in our understanding of its genetic control and molecular biology, as well as pre-clinical and clinical research. It also presents state-of-the-art diagnostic approaches and therapeutic options, and an open discussion on the future prospects for patient management. Malignant mesothelioma is an enormous global health problem related to asbestos exposure. Despite the best efforts of scientists and oncologists, the prognosis for those affected remains poor. Due to anatomical characteristics and non-specific symptoms, the diagnosis of mesothelioma at an early stage is often difficult, while surgery and radiotherapy are only of limited use, even if some multimodality approaches seem promising. In turn, medical treatments are sometimes successful in tumor control, but have little impact on overall survival. However, advances in our understanding of the disease’s biology, together with the availability of new drugs and combinations, make mesothelioma an essential and highly topical field for pre-clinical and clinical studies. This book is subdivided into four parts: epidemiology and preclinical data, diagnosis, therapy, and extrathoracic mesothelioma. It highlights the progress made in a variety of areas – e.g. in vitro and in vivo experimental models, genetics, environment, biomarkers, targeting agents, immunotherapy, metabolic imaging and ongoing clinical trials – and describes the standard clinical management of mesothelioma patients, including those with extra-thoracic localizations. Given its scope, the book offers an invaluable tool for researchers, oncologists and clinicians alike.

Mesothelioma is an aggressive cancer with very poor survival and lack of treatment options. This book, written by a diverse panel of experts, presents a description of the most relevant topics on epidemiology, diagnosis, biomarkers, and treatment updates, including interesting discussion on molecular mechanisms, prognostic features, and novel therapies that are either approved or under clinical development for this challenging disease. It also discusses and explains genetic biomarkers, as there may be a role for some nuclear regulatory genes and proteins in development of mesothelioma, although targeted therapies so far have had limited impact.

Combination Therapy against Multidrug Resistance explores the potential of combination therapy as an efficient strategy to combat multi-drug resistance. Multidrug resistance (MDR) occurs when microorganisms such as bacteria, fungi, viruses, and parasites are excessively exposed to antimicrobial drugs such as antibiotics, antifungals, or antivirals, and in response the microorganism undergoes mutations or develops different resistance mechanisms to combat the drug for its survival. MDR is becoming an increasingly serious problem in both developed and developing nations. Bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat, and the same is true for a variety of other diseases. Combination therapy proves to be a promising strategy as it offers potential benefits such as a broad spectrum of efficacy, greater potency than the drugs used in monotherapy, improved safety and tolerability, and reduction in the number of resistant organisms. This book considers how combination therapy can be applied in multiple situations, including cancer, HIV, tuberculosis, fungal infections, and more. Combination Therapy Against Multidrug Resistance gathers the most relevant information on the prospects of combination therapy as a strategy to combat multridrug resistance and helping to motivate the industrial sector and government agencies to invest more in research and development of this strategy as a weapon to tackle the multidrug resistance problem. It will be useful to academics and researchers involved in the development of new antimicrobial or antiinfective agents and treatment strtategies to combat multidrug resistance. Clinicians and medical nurses working in the field of infection prevention and control (IPC) will also find the book relevant - Explores strategic methods with investigation of both short- and long-term goals to combat multidrug resistance - Presents a broad scope to understand fully the ways to apply combined therapy to multidrug resistance - Provides an overview of combination therapy, but also includes specific cases such as cancer, tuberculosis, HIV and malaria

In June 1997, Paul Kraus was diagnosed with mesothelioma, a very aggressive cancer, and given only a few months to live. More than eight years later, Mr. Kraus is alive with a good quality of life having rejected surgery, radiation, and chemotherapy. Here, the author offers solid practical advice on: how to cope with the initial diagnosis; nutrition and diet; conventional and complementary therapies; the role of the mind in health and the principles of healing.--From publisher description.

This book is a state-of-the-art overview of cancer regional therapy (CRT) for the surgeons and interventional radiologists active in CRT development and research. The goals of this book are 1) to review the theory and practice of cancer regional therapies including pharmacology, devices, techniques, and workflow, 2) illustrate the most common procedures performed in the interventional and operating rooms, and 3) discuss data supporting use of CRT. This is meant to be a definitive text on the theory and practice of CRT. It begins with a summary of the history, technical principles that underlie regional therapy. The following parts discuss current data and practice in peritoneal, liver, limb, pleural and other sites. Included in the practice are considerations of workflow and financial issues revolving around CRT. Novel techniques and therapies under investigation are presented to inform the direction of the field. Cancer Regional Therapy summarizes the history, current technology, common procedures, and future prospects in this field and includes procedures from many surgical and interventional radiologic disciplines.